Sam Altman Takes the Stand as OpenAI’s Safety Mission Faces Scrutiny in Musk Lawsuit

OpenAI CEO Sam Altman testified in court against a lawsuit brought by co-founder Elon Musk, who alleges that the creation of OpenAI’s for-profit subsidiary amounted to misappropriating a charitable organisation built around safe AI development.

Altman pushed back on that framing, arguing that OpenAI had built one of the world’s largest charitable foundations and that its safety mission remained intact as the company grew commercially. He testified that it was in fact Musk who had raised concerns during early internal debates — stating that Musk’s own positions on safety and control gave him pause, particularly remarks suggesting OpenAI’s assets might one day pass to Musk’s children.

Altman also described Musk’s management approach as damaging to OpenAI’s research culture, alleging that his tactics demotivated key staff. OpenAI board chair Bret Taylor separately addressed questions about the foundation’s delayed staffing, attributing it to the complexity of converting equity into cash ahead of the 2025 restructuring.

Musk left OpenAI’s board before later founding rival AI venture xAI.

Need Deeper Intelligence on the AI Market?

AI Insider's Market Intelligence platform tracks funding rounds, competitive landscapes, and technology trends across the global AI ecosystem in real time. Get the data and insights your organization needs to make informed decisions.

Related Articles

Anthropic Expands Claude for Legal With AI Plug-Ins and MCP Connectors for Law Firms

Anthropic has launched a new set of AI-powered tools for the legal sector, expanding its Claude for Legal platform with specialised plug-ins and Model Context

Frame Security Launches with $50M to Build the Future of Human Security

Insider Brief PRESS RELEASE — Frame Security, has announced its public launch alongside a $50 million funding round led by Index Ventures, Team8, and Picture

Isomorphic Labs Announces $2.1B Funding to Scale its AI Drug Design Engine

Insider Brief PRESS RELEASE — Isomorphic Labs, an AI-first drug design and development company, has announced it has raised $2.1 Billion in Series B funding.

Stay Updated with AI Insider

Get the latest AI funding news, market intelligence, and industry insights delivered to your inbox weekly.

$ 0 M

Seed round tracked

Gitar — Code Validation

Get the Weekly Briefing

Funding analysis, market intelligence, and industry trends delivered to your inbox every week.

Need bespoke intelligence?

Our team combines real-time data with decades of sector experience to guide your decisions.

Subscribe today for the latest news about the AI landscape